Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
gene therapy |
| gptkbp:approvedForUse |
no (as of 2024, in most countries)
|
| gptkbp:canBeAllogeneic |
true
|
| gptkbp:canBeAutologous |
true
|
| gptkbp:canBeEngineered |
true
|
| gptkbp:clinicalTrialPhase |
ongoing
|
| gptkbp:combines |
chemotherapy
monoclonal antibodies checkpoint inhibitors |
| gptkbp:goal |
enhance anti-tumor immunity
|
| https://www.w3.org/2000/01/rdf-schema#label |
NK Cell Therapy
|
| gptkbp:mechanismOfAction |
cytotoxicity against tumor cells
release of cytokines |
| gptkbp:regulates |
investigational
|
| gptkbp:relatedTo |
gene therapy
CAR-NK cell therapy |
| gptkbp:sideEffect |
cytokine release syndrome
infusion reactions |
| gptkbp:source |
induced pluripotent stem cells
peripheral blood umbilical cord blood NK cell lines |
| gptkbp:studiedBy |
academic institutions
pharmaceutical companies biotechnology companies |
| gptkbp:treatment |
gptkb:cancer
solid tumors hematological malignancies |
| gptkbp:uses |
gptkb:natural_killer_cells
|
| gptkbp:bfsParent |
gptkb:Cell_Therapy
|
| gptkbp:bfsLayer |
6
|